Seer (SEER) Operating Income (2020 - 2026)
Seer (SEER) posted quarterly Operating Income of -$17.3 million for Q1 2026, up 16.76% year-over-year from -$14.8 million in Q1 2025, and up 0.74% quarter-over-quarter from -$17.4 million in Q4 2025.
Analysis
Seer (SEER) Operating Income (2020 - 2026) Analysis & Trends
Seer's Operating Income history runs 7 years deep, the most recent figure standing at -$17.3 million for Q1 2026.
- In Q1 2026, Operating Income rose 16.76% year-over-year to -$17.3 million; the TTM figure through Mar 2026 stood at -$74.5 million (up 22.09% YoY), while the FY2025 annual figure was -$78.0 million, up 22.09% from the prior year.
- Operating Income for Q1 2026 stood at -$17.3 million, up from -$17.4 million in the prior quarter.
- The five-year high for Operating Income was -$17.3 million in Q1 2026, with the low at -$27.9 million in Q2 2023.
- The 5-year median for Operating Income is -$23.8 million (2022), against an average of -$23.3 million.
- The sharpest annual moves came in 2022 and 2025: Operating Income sank 44.18% in 2022, then gained 25.98% in 2025.
- Seer's Operating Income stood at -$24.9 million in 2022, then gained by 10.89% to -$22.2 million in 2023, then declined by 5.65% to -$23.5 million in 2024, then gained by 25.98% to -$17.4 million in 2025, then advanced by 0.74% to -$17.3 million in 2026.
- Business Quant data shows SEER's Operating Income at -$17.3 million in Q1 2026, -$17.4 million in Q4 2025, and -$19.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Seer | 107.29 Mn | 107.29 Mn | 1.51 Mn | -16.84 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16.84 Mn |
| Mar 31, 2026 | -17.26 Mn |
| Dec 31, 2025 | -17.39 Mn |
| Sep 30, 2025 | -19.35 Mn |
| Jun 30, 2025 | -20.53 Mn |
| Mar 31, 2025 | -20.73 Mn |
| Dec 31, 2024 | -23.49 Mn |
| Sep 30, 2024 | -24.33 Mn |
| Jun 30, 2024 | -27.10 Mn |
| Mar 31, 2024 | -25.19 Mn |
| Dec 31, 2023 | -22.23 Mn |
| Sep 30, 2023 | -25.85 Mn |
| Jun 30, 2023 | -27.94 Mn |
| Mar 31, 2023 | -27.45 Mn |
| Dec 31, 2022 | -24.95 Mn |
| Sep 30, 2022 | -25.07 Mn |
| Jun 30, 2022 | -23.43 Mn |
| Mar 31, 2022 | -23.79 Mn |
| Dec 31, 2021 | -19.87 Mn |
| Sep 30, 2021 | -18.43 Mn |